Global Adoptive Cellular ImmunOthersapy Market Growth (Status and Outlook) 2025-2031

According to this study, the global Adoptive Cellular ImmunOthersapy market size will reach US$ million by 2031.

Adoptive cellular immunity is the transfer of lymphocytes from the donor to the recipient to enhance its cellular immunity.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Adoptive Cellular ImmunOthersapy Industry Forecast” looks at past sales and reviews total world Adoptive Cellular ImmunOthersapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Adoptive Cellular ImmunOthersapy sales for 2025 through 2031. With Adoptive Cellular ImmunOthersapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adoptive Cellular ImmunOthersapy industry.

This Insight Report provides a comprehensive analysis of the global Adoptive Cellular ImmunOthersapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Adoptive Cellular ImmunOthersapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Adoptive Cellular ImmunOthersapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adoptive Cellular ImmunOthersapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adoptive Cellular ImmunOthersapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Adoptive Cellular ImmunOthersapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
TIL
LAK
CAR-T
TCR-T
CIK
NK
DC
Others

Segmentation by Application:
Hospital
Cancer Hospital
Centers for Disease Control and Prevention
Rehabilitation Center
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen Inc
Autolus Therapeutics Plc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
bluebird bio Inc
CARsgen Therapeutics Ltd
Celgene Corp
Cell Medica Ltd
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Daiichi Sankyo Co Ltd
Fosun Pharmaceutical AG
Gilead Sciences Inc
Guangzhou Anjie Biomedical Technology Co Ltd
Hangzhou Converd Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HRAIN Biotechnology Co Ltd
Juno Therapeutics Inc
Kite Pharma Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nkarta Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Sorrento Therapeutics Inc
Takara Bio Inc

Please note: The report will take approximately 2 business days to prepare and deliver. Show more